July 26th 2024
The CAR T-cell therapy UCART22 has been granted orphan drug designation and rare pediatric drug designation from the FDA for the treatment of acute lymphoblastic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Luspatercept Lessens RBC Transfusion Burden in MDS
September 7th 2023Results from the COMMANDS trial led the FDA to approve luspatercept for the treatment of anemia without prior erythropoiesis-stimulating agent use in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions.
Read More
Frontline Therapy in Lymphoma: Key Takeaways From POLARIX and SWOG S1826
August 31st 2023Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, share key takeaways from their program with Jonathan Friedberg, MD, MMSc, on practice-changing data from the POLARIX and SWOG S1826 clinical trials.
Watch
DLBCL: Real-World Use of Frontline Polatuzumab Vedotin Following the POLARIX Trial
August 31st 2023Following their discussion on the phase 3 POLARIX trial in DLBCL, Jonathan Friedberg, MD, MMSc, and the Oncology Brothers consider how frontline polatuzumab vedotin will be used in the real-world setting.
Watch
Roundtable Roundup: Graft-vs-Host Disease
August 31st 2023In separate live virtual events, Pashna N. Munshi, MD; Navneet Majhail, MD, MS; and participants at the respective discussions considered treatment options for a patient with chronic graft-vs-host disease (GVHD) after multiple previous treatment attempts.
Read More
Considering Outpatient Use of Tagraxofusp for BPDCN in the Community Setting
August 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with other oncologists concerning the practical considerations for outpatient use of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasm.
Read More